Drug Profile
Aprocitentan - Idorsia Pharmaceuticals
Alternative Names: AC 080; ACT-132577; JNJ-2820; TRYVIOLatest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Developer Idorsia Pharmaceuticals
- Class Amides; Antihypertensives; Cardiovascular therapies; Ethers; Halogenated hydrocarbons; Pyrimidines; Small molecules
- Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Hypertension
- Phase II Essential hypertension
Most Recent Events
- 22 Mar 2024 Idorsia Pharmaceuticals has patent protection for the process of manufacture and use of Aprocitentan in USA and rest of the World (Idorsia Pharmaceuticals website, March 2024)
- 20 Mar 2024 Idorsia Pharmaceuticals plans to launch aprocitentan for Hypertension in the second half of 2024
- 20 Mar 2024 The US FDA approves the Risk Evaluation and Mitigation Strategy (REMS) for Aprocitentan